VTVT stock moved higher in early trading on February 10, 2020, after the company said it acheived its primary objective in a Phase 2 study of TTP399.
TTP399 is a book, liver-selective glucokinase activator taken once every day. The 12-week trial investigated the effectiveness and security of 800 milligrams of TTP399 in comparison with placebo in 85 individuals with type 1 diabetes on improved insulin treatment. The analysis was conducted with assistance from JDRF International (JDRF), the leading supplier of T1D research financing internationally.
The trial achieved its main objective analyzed with two statistical methods for assessing the impact of TTP399. The principal statistical investigation evaluated the impact on HbA1c irrespective of therapy adherence or noteworthy changes in insulin management. Beneath the key statistical evaluation, the trial achieved its main goal by showing statistically significant improvements in HbA1c (long-term blood glucose ) for TTP399 in comparison to placebo at week 12 (p=0.03).
TTP399 was well tolerated with similar incidences of both treatment-emergent adverse events general and by system organ class in the two treatment groups. There was no incidence of acute hypoglycemia in the treated group and a single episode in the placebo group. Patients carrying TTP399 undergone fewer symptomatic hypoglycemic episodes: 2 issues carrying TTP399 reported at least one occasion in contrast to eight subjects taking placebo.